Tag Archives: Initial Public Offering

Business, Finance, Occupation & Industry

Cancer Genetics, Inc. Announces Closing of Initial Public Offering of 690,000 Shares of Common Stock

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Cancer Genetics, Inc. Announces Closing of Initial Public Offering of 690,000 Shares of Common Stock

RUTHERFORD, N.J.–(BUSINESS WIRE)– Cancer Genetics, Inc. (OTCQB: CGIX), a diagnostics company focused on developing genomic-based, oncology tests and services, today announced it has closed its initial public offering of 690,000 shares of common stock (including 90,000 shares that were offered and sold by Cancer Genetics pursuant to the exercise in-full of the underwriters’ over-allotment option) at a price to the public of $10.00 per share. Total gross proceeds from the offering were $6,900,000, before deducting underwriting discounts and commissions and other offering expenses payable by Cancer Genetics.

Aegis Capital Corp. acted as sole book-running manager for the offering.

Feltl and Company, Inc. acted as co-manager for the offering.

This offering was made only by means of a prospectus. Copies of the prospectus relating to this offering may be obtained by contacting Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 18th Floor, New York, NY 10019, telephone: 212-813-1010, e-mail: prospectus@aegiscap.com.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on April 4, 2013. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Cancer Genetics:

Cancer Genetics, Inc. is an early-stage diagnostics company focused on developing and commercializing proprietary genomic tests and services to improve and personalize the diagnosis, prognosis and response to treatment (theranosis) of cancer. The proprietary tests being developed by Cancer Genetics target cancers that are difficult to prognose and predict treatment outcomes using currently available mainstream techniques. These cancers include hematological, urogenital and HPV-associated cancers. Cancer Genetics recently has begun to provide its proprietary tests and services along with a comprehensive range of non-proprietary oncology-focused tests and laboratory services that it has provided historically to oncologists and pathologists at hospitals, cancer centers and physician offices. Cancer Genetics is currently offering its tests and laboratory services in its 17,936 square foot laboratory located in Rutherford, New Jersey, which has been accredited under the Clinical Laboratory Improvement Amendments of 1988 to perform high complexity testing.

Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

Taylor Morrison Home Corporation Announces Pricing of Initial Public Offering

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Taylor Morrison Home Corporation Announces Pricing of Initial Public Offering

SCOTTSDALE, Ariz.–(BUSINESS WIRE)– Taylor Morrison Home Corporation (NYS: TMHC) today announced the pricing of its initial public offering of 28,572,000 shares of the Company’s Class A common stock at a price to the public of $22.00 per share. The shares will be listed on the New York Stock Exchange and will trade under the ticker symbol “TMHC” beginning on April 10, 2013. The underwriters also have a 30-day option to purchase up to an additional 4,285,800 shares of the Company’s Class A common stock at the initial public offering price less the underwriting discount. The offering is expected to close on April 12, 2013.

Total net proceeds to the Company from the offering, after deducting the underwriting discount, will be approximately $590.9 million. The Company intends to use approximately $204.3 million of the net proceeds to purchase ownership interests in its direct operating subsidiary whose subsidiaries will then use those proceeds to redeem approximately $189.6 million of their outstanding senior notes. The Company intends to use the remaining approximately $386.6 million of the net proceeds, together with cash on hand, to purchase additional ownership interests in its direct operating subsidiary from its current equity sponsors and certain members of management.

Credit Suisse Securities (USA) LLC, Citigroup Global Markets Inc., Deutsche Bank Securities Inc., Goldman, Sachs & Co., J.P. Morgan Securities LLC and Zelman Partners LLC are acting as joint book-running managers for the offering.

The offering of these securities was made only by means of a prospectus, copies of which may be obtained from the offices of:

Credit Suisse Securities (USA) LLC
Attn: Prospectus Department
One Madison Avenue
New York, NY 10010-3629
(800) 221-1037
newyork.prospectus@credit-suisse.com

Citigroup Global Markets Inc.
Attention: Broadridge Financial Solutions
1155 Long Island Avenue
Edgewood, New York 11717
(800) 831-9146

Deutsche Bank Securities Inc.
Attention: Prospectus Group
60 Wall Street
New York, New York 10005-2836
(800) 503-4611
prospectus.cpdg@db.com

Goldman, Sachs & Co.
Attn: Prospectus Department
200 West Street
New York, NY 10282
(866) 471-2526
prospectus-ny@ny.email.gs.com

J.P. Morgan Securities LLC
Attention: Broadridge Financial Solutions
1155 Long Island Avenue
Edgewood, New York 11717
(866) 803-9204

A registration statement relating to the common shares has been filed with, and declared effective by, the Securities and Exchange Commission. This press release does not constitute an offer to sell, or the solicitation of an …read more

Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

Cancer Genetics, Inc. Announces Pricing of Initial Public Offering of 600,000 Shares of Common Stock

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Cancer Genetics, Inc. Announces Pricing of Initial Public Offering of 600,000 Shares of Common Stock

RUTHERFORD, N.J.–(BUSINESS WIRE)– Cancer Genetics, Inc., a diagnostics company focused on developing genomic-based, oncology tests and services, today announced the pricing of its initial public offering of 600,000 shares of its common stock at a price to the public of $10.00 per share. The gross proceeds to Cancer Genetics from the initial public offering are expected to be $6,000,000 (assuming no exercise of the over-allotment option), before underwriting discounts and commissions and other offering expenses payable by Cancer Genetics. Cancer Genetics has granted the representative of the underwriters a 45-day option to purchase up to 90,000 additional shares of common stock from Cancer Genetics to cover over-allotments, if any. Shares of Cancer Genetics‘ common stock are expected to be quoted on the OTCQB Marketplace, operated by OTC Markets Group, under the symbol “CGIX” beginning on April 5, 2013. Investors will be able to find Real Time Level II quotes for “CGIX” on www.otcmarkets.com.

The offering is expected to close on April 10, 2013, subject to customary closing conditions.

Aegis Capital Corp. is acting as sole book-running manager for the offering.

Feltl and Company, Inc. is acting as co-manager for the offering.

This offering is being made only by means of a prospectus. Copies of the prospectus relating to this offering may be obtained by contacting Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 18th Floor, New York, NY 10019, telephone: 212-813-1010, e-mail: prospectus@aegiscap.com.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on April 4, 2013. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Cancer Genetics:

Cancer Genetics, Inc. is an early-stage diagnostics company focused on developing and commercializing proprietary genomic tests and services to improve and personalize the diagnosis, prognosis and response to treatment (theranosis) of cancer. The proprietary tests being developed by Cancer Genetics target cancers that are difficult to prognose and predict treatment outcomes by using currently available mainstream techniques. These cancers include hematological, urogenital and HPV-associated cancers. Cancer Genetics recently …read more

Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

Phillips 66 Partners Files Registration Statement for Initial Public Offering

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Phillips 66 Partners Files Registration Statementfor Initial Public Offering

HOUSTON–(BUSINESS WIRE)– Phillips 66 Partners LP, a wholly owned subsidiary of Phillips 66 (NYS: PSX) , has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) related to its proposed initial public offering of common units representing limited partner interests. The offering is expected to occur in the second half of this year. Phillips 66 Partners anticipates the common units will trade on the New York Stock Exchange under the ticker symbol “PSXP”. The number of common units to be offered and the price range for the offering have not yet been determined. Phillips 66 Partners expects to receive gross proceeds from the offering in the amount of approximately $300 million, excluding proceeds from any exercise of the underwriters’ over-allotment option to purchase additional common units.

Phillips 66 formed Phillips 66 Partners to own, operate, develop and acquire primarily fee-based crude oil, refined petroleum product and natural gas liquids pipelines and terminals and other transportation and midstream assets. Headquartered in Houston, Phillips 66 Partners expects its initial assets to include the Clifton Ridge crude oil pipeline, terminal and storage system in Louisiana; the Sweeny to Pasadena refined petroleum product pipeline, terminal and storage system in Texas; and the Hartford Connector refined petroleum product pipeline, terminal and storage system in Illinois.

J.P. Morgan and Morgan Stanley are acting as joint book-running managers for the proposed offering. The offering will be made only by means of a prospectus. Once it becomes available, potential investors can obtain a preliminary prospectus related to this offering from:

<td …read more
Source: FULL ARTICLE at DailyFinance

J.P. Morgan

Business, Finance, Occupation & Industry

Enanta Pharmaceuticals Announces Closing of Initial Public Offering and Exercise of Underwriters' Ov

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Enanta Pharmaceuticals Announces Closing of Initial Public Offering and Exercise of Underwriters’ Over-Allotment Option

WATERTOWN, Mass.–(BUSINESS WIRE)– Enanta Pharmaceuticals, Inc. (NAS: ENTA) , a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced the closing of its initial public offering of 4,600,000 shares of its common stock at a price to the public of $14.00 per share, which includes the exercise in full by the underwriters of their over-allotment option to purchase up to 600,000 additional shares of common stock. Enanta Pharmaceuticals common stock is listed on the NASDAQ Global Select Market under the trading symbol “ENTA”. All of the shares in the offering were offered by Enanta Pharmaceuticals.

J.P. Morgan Securities LLC and Credit Suisse Securities (USA) LLC acted as joint book-running managers for the offering. Leerink Swann LLC and JMP Securities LLC acted as co-managers.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on March 20, 2013. This offering was made solely by means of a prospectus. A copy of the final prospectus relating to the offer may be obtained by contacting J.P. Morgan Securities LLC via Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by calling toll-free (866) 803-9204; or Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, One Madison Avenue, New York, NY 10010, or by calling toll-free (800) 221-1037, or by emailing newyork.prospectus@credit-suisse.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction

About Enanta

Enanta Pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs in the infectious disease field. Enanta is discovering and developing novel inhibitors designed for use against the hepatitis C virus (HCV). These inhibitors include members of the direct acting antiviral (DAA) inhibitor classes – protease (partnered with AbbVie), NS5A (partnered with Novartis) and nucleotide polymerase – as well as a host-targeted antiviral (HTA) inhibitor class targeted against cyclophilin. Additionally, Enanta has created a new class of antibiotics, called Bicyclolides, for the treatment of multi-drug resistant bacteria, with …read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

Enanta Pharmaceuticals Announces Pricing of Initial Public Offering

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Enanta Pharmaceuticals Announces Pricing of Initial Public Offering

WATERTOWN, Mass.–(BUSINESS WIRE)– Enanta Pharmaceuticals, Inc. (NAS: ENTA) , a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced the pricing of its initial public offering of 4,000,000 shares of its common stock at a price to the public of $14.00 per share. The shares of Enanta’s common stock will trade on the NASDAQ Global Select Market under the symbol “ENTA” beginning on March 21, 2013. All of the shares of common stock are being offered by Enanta. In addition, Enanta has granted the underwriters a 30-day option to purchase up to an additional 600,000 shares of common stock to cover over-allotments, if any. The offering is expected to close on March 26, 2013, subject to customary closing conditions.

J.P. Morgan Securities LLC and Credit Suisse Securities (USA) LLC are acting as joint book-running managers for the offering. Leerink Swann LLC and JMP Securities LLC are acting as co-managers.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on March 20, 2013.

The offering will be made only by means of a prospectus. Copies of the prospectus relating to the offering may be obtained from J.P. Morgan Securities LLC via Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by calling toll-free (866) 803-9204; or Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, One Madison Avenue, New York, NY 10010, or by calling toll-free (800) 221-1037, or by emailing newyork.prospectus@credit-suisse.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About Enanta

Enanta Pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs in the infectious disease field. Enanta is discovering and developing novel inhibitors designed for use against the hepatitis C virus (HCV). These inhibitors include members of the direct acting antiviral (DAA) inhibitor classes – protease (partnered with AbbVie), NS5A (partnered with Novartis) and nucleotide polymerase – as well as a host-targeted antiviral (HTA) …read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

Tetraphase Pharmaceuticals Announces Pricing of Initial Public Offering

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Tetraphase Pharmaceuticals Announces Pricing of Initial Public Offering

WATERTOWN, Mass.–(BUSINESS WIRE)– Tetraphase Pharmaceuticals, Inc. (Nasdaq: TTPH) today announced the pricing of its initial public offering of 10,714,286 shares of common stock at a price to the public of $7.00 per share, less underwriting discounts and commissions. Tetraphase’s common stock is expected to begin trading on the NASDAQ Global Market under the symbol “TTPH” on March 20, 2013.

Tetraphase has granted the underwriters a 30-day option to purchase up to 1,607,143 additional shares of common stock at the same price to cover over allotments, if any.

Barclays and BMO Capital Markets are acting as joint book-running managers. Stifel, JMP Securities and Needham & Company are acting as co-managers for the offering. A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission (SEC). The offering is being made only by means of a prospectus. A copy of the final prospectus relating to these securities will be filed with the SEC and may be obtained, when available, from: Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by calling (888) 603-5847, or by emailing barclaysprospectus@broadridge.com, or by calling BMO Capital Markets at (800) 414-3627, or by emailing bmoprospectus@bmo.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Tetraphase Pharmaceuticals, Inc.

Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening multi-drug resistant infections. Tetraphase’s lead product candidate, eravacycline, is a fully synthetic tetracycline derivative being developed as a broad-spectrum intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multi-drug resistant infections, including multi-drug resistant Gram-negative infections.

Tetraphase Pharmaceuticals
David Lubner
Senior Vice President & CFO
617-715-3551
dlubner@tphase.com
or
For media:
Sam Brown Inc.
Mike Beyer
773-463-4211
beyer@sambrown.com

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:

The article Tetraphase Pharmaceuticals Announces Pricing …read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

Model N Announces Pricing of Initial Public Offering

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Model N Announces Pricing of Initial Public Offering

Shares to Trade on NYSE under Ticker Symbol “MODN”

REDWOOD CITY, Calif.–(BUSINESS WIRE)– Model N, Inc., a provider of revenue management solutions for the life science and technology industries, today announced the pricing of its initial public offering of 6,740,000 shares of its common stock, including 6,000,000 shares from the company and 740,000 shares from a selling stockholder, at a price to the public of $15.50 per share. The shares are expected to begin trading on the New York Stock Exchange on March 20, 2013, under the symbol “MODN.” In addition, the company has granted the underwriters a 30-day option to purchase up to 1,011,000 additional shares of common stock.

J.P. Morgan Securities LLC and Deutsche Bank Securities Inc. are acting as joint bookrunning managers for the offering, and Stifel, Nicolaus & Company, Incorporated, Pacific Crest Securities LLC, Piper Jaffray & Co. and Raymond James & Associates, Inc. are acting as co-managers for the offering.

The offering will be made only by means of a prospectus. A copy of the final prospectus relating to the offering may be obtained from: J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, Phone: (866) 803-9204; or Deutsche Bank Securities Inc., 60 Wall Street, New York, New York 10005, Attention: Prospectus Department, by calling (800) 503-4611, or by e-mailing prospectus.cpdg@db.com.

A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Investor Relations Contact:
ICR for Model N
Greg Kleiner, 650-610-4998
investorrelations@modeln.com
or
Media Contact:
Model N
Kristin Lee, 650-610-4717
Marketing
klee@modeln.com

KEYWORDS:   United States  North America  California

INDUSTRY KEYWORDS:

The article Model N Announces Pricing of Initial Public Offering originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that <a target=_blank …read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

Silver Spring Networks Announces the Closing of its Initial Public Offering and Full Exercise of the

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Silver Spring Networks Announces the Closing of its Initial Public Offering and Full Exercise of the Underwriters’ Over-Allotment Option

REDWOOD CITY, Calif.–(BUSINESS WIRE)– Silver Spring Networks, Inc. (NYS: SSNI) , a leading networking platform and solutions provider for smart energy networks, today announced the closing of its previously announced initial public offering of 5,462,500 shares of common stock at a price to the public of $17.00 per share, which included 712,500 shares of common stock issued upon the exercise in full of the underwriters’ option to purchase additional shares to cover over-allotments. All of the shares sold in the offering were sold by Silver Spring Networks. The shares began trading on The New York Stock Exchange on March 13, 2013 under the symbol “SSNI.”

Goldman, Sachs & Co. and Credit Suisse Securities (USA) LLC acted as joint book-running managers for the offering and Stifel, Nicolaus & Company, Incorporated, Piper Jaffray & Co., Canaccord Genuity Inc., Evercore Group L.L.C., Pacific Crest Securities LLC and Robert W. Baird & Co. acted as co-managers.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on March 12, 2013. This offering was made solely by means of a prospectus. A copy of the final prospectus related to the offering may be obtained from: Goldman, Sachs & Co., Attention: Prospectus Department, 200 West Street, New York, NY 10282, telephone: 1-866-471-2526 or by emailing prospectus-ny@ny.email.gs.com or Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, One Madison Avenue, New York, New York 10010, telephone: 1-800-221-1037 or by emailing newyork.prospectus@credit-suisse.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Investor Contact
Silver Spring Networks, Inc.
Tricia Gugler,650-839-4504
Investor Relations
tgugler@silverspringnet.com
or
Media Contact
Global Communications
Noel Hartzell, 650-839-4184nhartzell@silverspringnet.com

KEYWORDS:   United States  North America  California

INDUSTRY KEYWORDS:

The article Silver Spring Networks Announces the Closing of its Initial Public Offering and Full Exercise of the Underwriters’ Over-Allotment Option originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We …read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

Higher One Holdings, Inc. Hires New Investor Relations Manager

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Higher One Holdings, Inc. Hires New Investor Relations Manager

NEW HAVEN, Conn.–(BUSINESS WIRE)– Higher One Holdings, Inc. (NYS: ONE) ,a leader in providing financial services and data analytics to over 1,300 college and university campuses across the U.S., announced today the hiring of Joseph Villalta to the position of Investor Relations Manager. Joseph will be responsible for developing and implementing Higher One‘s investor relations strategy and its day-to-day contact with the investment community. He will report to Christopher Wolf, Chief Financial Officer.

“We are pleased to welcome Joseph to Higher One. His extensive background and investor relations experience is a great addition to the team as we continue to build on our capital market efforts,” said Mark Volchek, CEO of Higher One Holdings.

Joseph began his career in 2003 working as an associate at Brainerd Communicators where he supported the Investor Relations programs for large-cap media companies such as Cablevision, Comcast, Pixar Animation Studios and Liberty Media. He then joined The Ruth Group (TRG) in 2005, where he led the Investor Relations practice for the firm’s Technology clients. While at TRG, Joseph built award winning programs for companies such as NETGEAR, Inc., Freescale Semiconductor, MagnaChip and Sina.com. Following his seven year tenure at TRG, he joined Dresden, Germany-based Novaled AG, where he focused on creating the Investor Relations infrastructure to reflect Novaled’s intended U.S. Initial Public Offering.

About Higher One Holdings, Inc.

Higher One Holdings, Inc. (NYS: ONE) is a leading company focused on creating cost-saving efficiencies for higher education institutions and providing high-value services to students. Higher One offers a wide array of technological services on campus, ranging from streamlining the institution’s performance analytics and financial aid refund processes to offering students innovative banking services, tuition payment plans, and the basics of financial management. Higher One works closely with colleges and universities to allocate resources more efficiently in order to provide a higher quality of service and education to students.

Founded in 2000 on a college campus by students, Higher One now serves more than half of the higher education market, providing its services to over 1,300 campuses and 10.9 million students at distinguished public and private institutions nationwide. More information about Higher One can be found at www.ir.higherone.com.

…read more
Source: FULL ARTICLE at DailyFinance